Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Cash from Financing Activities of -$1.7 million for Q1 2026, down 50.76% year-over-year from -$3.4 million in Q1 2025, and down 42075.0% quarter-over-quarter from -$4000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Cash from Financing Activities data on file, last reported at -$1.7 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$1.7 million, down 50.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 129.05% YoY), and the FY2025 annual result was -$2.0 million, down 40.96% from the prior year.
- Cash from Financing Activities slipped to -$1.7 million in Q1 2026 per AMRN's latest filing, from -$4000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $364000.0 in Q1 2023 and troughed at -$1.7 million in Q1 2026.
- A 5-year average of -$312529.4 and a median of -$68000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 172.08% in 2023, then sank 2050.0% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $38000.0 in 2022, then surged by 118.42% to $83000.0 in 2023, then tumbled by 79.52% to $17000.0 in 2024, then sank by 123.53% to -$4000.0 in 2025, then tumbled by 42075.0% to -$1.7 million in 2026.
- Business Quant data shows AMRN's Cash from Financing Activities at -$1.7 million in Q1 2026, -$4000.0 in Q4 2025, and -$248000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 366.70 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | -1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.69 Mn |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Jun 30, 2025 | -663,000.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.43 Mn |
| Dec 31, 2023 | 83,000.00 |
| Dec 31, 2023 | 83,000.00 |